CALQUENCE® PLUS VENETOCLAX APPROVED IN THE US AS FIRST ALL-ORAL, FIXED-DURATION COMBINATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE 1ST-LINE SETTING
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.